TCMD Tactile Systems Technology, Inc.
XNAS
26.09
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves- 52-Week Range
- $20.53 – $37.77
- YTD
- -4.78%
- IV Rank (30D)
- 27.86
- Straddle Price
- $3.20
- P/C Vol Ratio
- 0.18
- Market Cap
- $0.6B
- Open
- $26.41
- Day Range
- $25.81 – $26.80
- Volume
- 147,219
- Prev Close
- $26.42
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.19 |
| Cost of Equity (CAPM) | 11.71% (VRP-adj) |
| WACC | 11.59% |
| Volatility Risk Premium | +30.6pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 33.9% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | 10.5% |
| Book / Price | 37.9% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 77.0% |
| FCF Margin (TTM) | 8.1% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| Market-Implied Growth | +11.1% (reverse-DCF on current price) |
| SMA 50 | $23.53 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $25.11 |
| Bollinger Width / SMA20 | 24.9% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $10.44 | 37% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $16.93 | 11% | median 16.6× · 3 peers |
| Peer EV/EBITDA | $20.77 | 11% | median 9.5× · 4 peers |
| Peer P/B | $30.37 | 11% | median 3.1× · 4 peers |
| Peer P/S | $15.23 | 11% | median 1.0× · 4 peers |
| Market Anchor (SMA50) | $23.53 | 19% | stability 26% (BB-width) |
| Options Expected (B-L 30d) | $26.50 | 0% | 5 strikes · skew -1.23 |
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.6B
- Employees
- 1,086
- List Date
- 2016-07-28
- CIK
- 0001027838
- Last Earnings
- Nov 2 after close · +8.4% vs ±21.8% expected
- Next Earnings
- ~Feb 16, 2027 (estimated)
- Headquarters
- Minneapolis, MN
- Homepage
- https://www.tactilemedical.com
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 18.15% | -20.07% | 9.45% | 6.53% | 2.28% | 5.33% | 3.61% |
| Feb | -8.25% | 30.35% | 9.72% | -3.30% | -17.59% | 1.95% | 2.15% |
| Mar | 3.03% | 0.15% | 13.48% | 5.86% | -6.17% | -10.79% | 0.93% |
| Apr | 7.24% | -21.49% | 11.43% | -12.13% | 3.82% | -11.36% | -3.75% |
| May | -8.30% | -43.27% | 13.19% | -11.23% | -28.56% | 7.51% | -11.78% |
| Jun | -2.79% | -25.74% | 13.84% | -6.86% | 2.53% | 24.19% | 0.86% |
| Jul | -7.46% | 10.40% | -5.91% | 11.92% | -2.44% | -8.42% | -0.32% |
| Aug | -8.10% | 2.74% | -16.92% | 10.05% | 37.93% | -22.83% | 0.48% |
| Sep | -0.69% | -5.12% | -26.44% | 8.22% | 2.90% | 0.18% | -3.49% |
| Oct | -24.91% | -6.77% | -21.50% | 1.47% | 8.97% | 6.13% | -6.10% |
| Nov | -44.82% | 22.11% | 13.83% | 33.02% | 63.03% | 15.52%* | 17.11% |
| Dec | -0.68% | 30.60% | 3.89% | -7.85% | 16.56% | -- | 8.50% |
| Total | -62.89% | -44.78% | 4.45% | 31.35% | 72.45% | -1.59% | -0.17% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: TCMD
Executive Summary BULLISH (Confidence Level: 7)
Key drivers:
- Strong technical signals, including SMA crossovers and MACD bullish momentum
- Positive news sentiment from recent headlines
- Moderate volatility, with a beta of 0.85
Primary risks:
- Potential for increased competition in the lymphedema solutions market
- Regulatory changes impacting the medical device industry
Investment thesis: TCMD is a well-positioned company with a strong pipeline of products and services focused on lymphedema management. The recent positive news headlines, combined with moderate volatility, create a favorable risk-reward environment for investors.
Recent news sentiment impact: The positive news headlines have contributed to the bullish momentum in TCMD's stock price, with a cumulative sentiment score of 3.5 out of 5 (POSITIVE).
Technical Analysis Trend Direction:
- Short-term: Bullish
- Medium-term: Bullish
- Long-term: Neutral
Support/Resistance Levels:
- SMA 20: $24.48 (resistance)
- SMA 50: $25.84 (resistance)
- Lower Bollinger Band: $22.32 (support)
Momentum Signals:
- RSI interpretation: Neutral, indicating no overbought or oversold conditions
- MACD signal: Bullish momentum, with a reading of -0.30 below the signal line
- Bollinger Bands position: Squeeze, indicating potential for increased volatility
Volume Analysis:
- Volume SMA 20: 376202.75 (increasing)
- On-Balance Volume (OBV): 2703591.28 (increasing)
- Volume Rate of Change: 102.01% (positive)
News & Sentiment Analysis Recent Headlines Summary:
- Positive news headlines from Tactile Medical's board expansion, product launches, and acquisitions
- Neutral headline about institutional support for small caps
Sentiment Assessment: Aggregate sentiment score: 3.5 out of 5 (POSITIVE)
Catalyst Identification: Upcoming earnings release and potential FDA approvals for new products
Market Narrative: The recent positive news headlines have contributed to the bullish momentum in TCMD's stock price, aligning with the company's strong technical signals.
Risk & Volatility Assessment Beta Interpretation: 0.85 (vs SPY), indicating moderate volatility
Volatility Regime: Current volatility is lower than historical levels
Options Market Signals:
- IV Rank: 18.0% (Low)
- Current IV: 90.0%
- Expected Move: $3.08 (38 DTE), 7-DTE: $1.73
- Volume Flow: 13 calls vs 4 puts
- Open Interest: 43 calls vs 4 puts
- Put/Call Volume Ratio: 0.31 (Bullish sentiment)
Downside Protection: Support levels at SMA 20 and Lower Bollinger Band
Market Context & Positioning Sector Performance: TCMD's sector, Medical Devices, has performed relatively well compared to the broader market
Institutional Activity: Increasing volume flow and open interest suggest institutional support for TCMD
Correlation Analysis: TCMD has a moderate correlation with the S&P 500 (R-squared interpretation)
Relative Valuation: TCMD is trading within its historical range, with no clear signs of overvaluation or undervaluation
Key Levels & Action Items Critical Price Levels:
- SMA 20: $24.48 (resistance)
- Lower Bollinger Band: $22.32 (support)
Breakout/Breakdown Levels: None identified
Time-Sensitive Catalysts: Upcoming earnings release and potential FDA approvals for new products
Risk Management: Stop-loss levels at SMA 50 and Lower Bollinger Band; position sizing considerations based on risk tolerance.
This comprehensive analysis provides a nuanced view of TCMD's stock, highlighting both the bullish momentum and potential risks. By referencing specific data points, we can gain insights into the company's technical and fundamental performance.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-23 | After-Close | 14.79% | 5.69% | 0.38x | Within |
| 2021-08-02 | After-Close | 9.81% | 8.02% | 0.82x | Within |
| 2021-11-08 | After-Close | 11.98% | 23.01% | 1.92x | Exceeded |
| 2022-02-22 | After-Close | 19.01% | 16.74% | 0.88x | Within |
| 2023-02-21 | After-Close | 6.56% | 10.73% | 1.64x | Exceeded |
| 2023-05-08 | After-Close | 16.70% | 13.34% | 0.80x | Within |
| 2023-08-07 | After-Close | 13.45% | 12.82% | 0.95x | Within |
| 2023-11-06 | After-Close | 11.08% | 21.22% | 1.92x | Exceeded |
| 2024-02-20 | After-Close | 25.70% | 2.25% | 0.09x | Within |
| 2024-04-23 | After-Close | 22.17% | 3.23% | 0.15x | Within |
| 2024-08-05 | Pre-Market | 39.97% | 5.87% | 0.15x | Within |
| 2024-11-04 | Pre-Market | 23.83% | 2.86% | 0.12x | Within |
| 2025-02-18 | After-Close | 14.70% | 13.27% | 0.90x | Within |
| 2025-05-05 | After-Close | 15.96% | 28.98% | 1.82x | Exceeded |
| 2025-08-04 | After-Close | 14.66% | 26.79% | 1.83x | Exceeded |
| 2025-11-03 | After-Close | 20.93% | 40.65% | 1.94x | Exceeded |
| 2026-02-17 | After-Close | 22.37% | 17.83% | 0.80x | Within |
| 2026-05-04 | After-Close | 19.28% | 7.22% | 0.37x | Within |
| 2026-08-10 | After-Close | 17.07% | 17.12% | 1.00x | Exceeded |
| 2026-11-02 | After-Close | 21.75% | 8.35% | 0.38x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
TCMD Options Activity & IV Rank
TCMD IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow · All expiries
ATM Options Pricing
Chain Summary
TCMD Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much TCMD actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Estimated net dealer gamma is at the 82nd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Above average volatility - stock moves with market amplification
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $8.0M | #1184 of 3151 | -24.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $1.7M | #3123 of 6285 | -13.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $3K | #4500 of 4858 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TCMD Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $976.78K | 56.67% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $744.50K | 43.20% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $2.23K | 0.13% | 2026-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $1.54M | 99.57% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $6.69K | 0.43% | 2026-09-30 |
TCMD Insider Trading (Form 4)
Latest: 2026-11-09| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-09 | William W Burke | Director | Sell (S) | −5,000 | $27.00 | -$135.0K | EDGAR |
| 2026-11-06 | Stephen A. Kiewiet | Chief Operating Officer | Award (A) | +6,438 | — | EDGAR | |
| 2026-11-05 | Laura G. King | Director | Sell (S) | −4,800 | $25.00 | -$120.0K | EDGAR |
| 2026-08-12 | Sheri Louise Dodd | Chief Executive Officer | Sell (S) | −10,978 | $29.44 | -$323.2K | EDGAR |
| 2026-05-13 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | Sell (S) | −4,631 | $24.49 | -$113.4K | EDGAR |
| 2026-05-08 | Laura G. King | Director | Award (A) | +6,521 | — | EDGAR | |
| 2026-05-08 | Carmen B Volkart | Director | Award (A) | +6,521 | — | EDGAR | |
| 2026-05-08 | Raymond Huggenberger | Director | Award (A) | +6,521 | — | EDGAR | |
| 2026-05-08 | Valerie L. Asbury | Director | Award (A) | +6,521 | — | EDGAR | |
| 2026-05-08 | William W Burke | Director | Award (A) | +6,521 | — | EDGAR | |
| 2026-05-08 | Andrea Pearson | Director | Award (A) | +6,521 | — | EDGAR | |
| 2026-05-08 | David Brent Shafer | Director | Award (A) | +6,521 | — | EDGAR | |
| 2026-05-08 | Boyd Vindell Washington | Director | Award (A) | +6,521 | — | EDGAR | |
| 2026-03-11 | Andrea Pearson | Director | Award (A) | +852 | — | EDGAR | |
| 2026-02-26 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | Sell (S) | −7,701 | $28.94 | -$222.9K | EDGAR |
TCMD Insider Holdings
13 insiders · @ $26.06| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Sheri Louise Dodd | Chief Executive Officer | 232,907 | $6.07M | -$1.20M | 13 | 2026-08-12 |
| 2 | Daniel L. Reuvers | President and CEO | 214,604 | $5.59M | -$1.18M | 15 | 2025-03-13 |
| 3 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | 130,188 | $3.39M | -$648.6K | 11 | 2026-05-13 |
| 4 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | 82,581 | $2.15M | -$779.2K | 16 | 2026-02-26 |
| 5 | Raymond Huggenberger | Director | 62,841 | $1.64M | $0 | 10 | 2026-05-08 |
| 6 | David Brent Shafer | Director | 55,343 | $1.44M | $0 | 6 | 2026-05-08 |
| 7 | Valerie L. Asbury | Director | 55,343 | $1.44M | $0 | 6 | 2026-05-08 |
| 8 | William W Burke | Director | 50,041 | $1.30M | -$1.82M | 25 | 2026-11-09 |
| 9 | Carmen B Volkart | Director | 44,219 | $1.15M | $0 | 5 | 2026-05-08 |
| 10 | Boyd Vindell Washington | Director | 41,768 | $1.09M | $0 | 4 | 2026-05-08 |
TCMD Board & Officers
As of SEC filings through Nov 9, 2026Directors 9
- William W Burke · since Jul 27, 2016
- Raymond Huggenberger · since Sep 20, 2017
- Sheri Louise Dodd · since Jan 1, 2021
- David Brent Shafer · since Jan 5, 2022
- Valerie L. Asbury · since Jan 5, 2022
- Carmen B Volkart · since Jan 5, 2023
- Boyd Vindell Washington · since Oct 2, 2023
- Laura G. King · since Jan 13, 2025
- Andrea Pearson · since Mar 9, 2026
Officers 4
- Sheri Louise Dodd · Chief Executive Officer · listed since Aug 2024
- Elaine M. Birkemeyer · Chief Financial Officer · since Mar 20, 2023
- Stephen A. Kiewiet · Chief Operating Officer · since Nov 2, 2026
- Kristie Burns · Sr. VP Mktg & Clinical Affairs · since May 1, 2021
Changes in the last 10 years (41)
| Nov 2, 2026 | Stephen A. Kiewiet became Chief Operating Officer |
| Mar 9, 2026 | Andrea Pearson became a director |
| Jan 13, 2025 | Laura G. King became a director |
| Aug 9, 2024 | Sheri Louise Dodd first listed as Chief Executive Officer in an SEC filing |
| Apr 23, 2024 | The company announced the departure of Daniel L. Reuvers as President and CEO in an SEC filing |
| Oct 2, 2023 | Boyd Vindell Washington became a director |
| Jul 31, 2023 | Sherri Lee Ferstler became Senior VP, Sales |
| Jul 14, 2023 | The company announced the departure of Eric Pauls as Senior VP, Sales in an SEC filing |
| Mar 20, 2023 | Elaine M. Birkemeyer became Chief Financial Officer |
| Mar 14, 2023 | The company announced the departure of Brent Moen as Chief Financial Officer in an SEC filing |
| Jan 5, 2023 | Carmen B Volkart became a director |
| Jan 5, 2022 | Valerie L. Asbury became a director |
| Jan 5, 2022 | The company announced the departure of Richard Nigon from the board in an SEC filing |
| Jan 5, 2022 | The company announced the departure of Peter H Soderberg from the board in an SEC filing |
| Jan 5, 2022 | The company announced the departure of Kevin H Roche from the board in an SEC filing |
| Jan 5, 2022 | David Brent Shafer became a director |
| May 1, 2021 | Kristie Burns became Sr. VP Mktg & Clinical Affairs |
| May 1, 2021 | Eric Pauls became Senior VP, Sales |
| Jan 1, 2021 | Sheri Louise Dodd became a director |
| Jan 1, 2021 | Deepti Jain became a director |
| Jun 8, 2020 | Daniel L. Reuvers became a director |
| Jun 8, 2020 | Daniel L. Reuvers became President and CEO |
| Sep 2, 2018 | Brent Moen became Chief Financial Officer |
| May 14, 2018 | Maggie Thompson listed as SVP, Reimb. & Payer Relations (previously SVP Payer Rltns & Govt Affr) in SEC filings |
| Mar 7, 2018 | Jordan Davis left the board, per their own SEC filing |
| Jan 3, 2018 | Maggie Thompson listed as SVP Payer Rltns & Govt Affr (previously VP Payer Rltns & Govt Affr) in SEC filings |
| Dec 6, 2017 | Bryan Rishe listed as SVP, Sales (previously Vice President, Sales) in SEC filings |
| Sep 20, 2017 | Raymond Huggenberger became a director |
| Sep 19, 2017 | Galen Partners V, L.L.C. reported in an SEC filing no longer being a 10% owner |
| Sep 19, 2017 | Galen Partners V LP reported in an SEC filing no longer being a 10% owner |
| Sep 19, 2017 | Galen Partners International V LP reported in an SEC filing no longer being a 10% owner |
| Sep 19, 2017 | Galen Management, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 15, 2017 | Radius Venture Partners III, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 15, 2017 | Radius Venture Partners III QP, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 15, 2017 | Radius Venture Partners III L P reported in an SEC filing no longer being a 10% owner |
| Sep 15, 2017 | Radius Venture Partners III (OHIO), LP reported in an SEC filing no longer being a 10% owner |
| Sep 15, 2017 | Daniel C Lubin reported in an SEC filing no longer being a 10% owner |
| Jul 28, 2017 | Cheryl Pegus became a director |
| Jun 7, 2017 | Mary E. Anderson reported in an SEC filing no longer being Vice President, Reimbursement |
| May 11, 2017 | Zubeen Shroff reported in an SEC filing no longer being a director |
| May 11, 2017 | Jordan Davis no longer listed as a 10% owner in SEC filings |
- Prev
- 1
Not reported recently (10)
- Daniel L. Reuvers · Last reported as a director in an SEC filing dated Mar 13, 2025
- Sherri Lee Ferstler · Last reported as Senior VP, Sales in an SEC filing dated Aug 14, 2024
- Deepti Jain · Last reported as a director in an SEC filing dated May 11, 2022
- Bryan Rishe · Last reported as SVP, Sales in an SEC filing dated Mar 9, 2021
- Cheryl Pegus · Last reported as a director in an SEC filing dated May 6, 2020
- Gerald R. Mattys · Last reported as a director in an SEC filing dated Apr 30, 2020
- Robert J. Folkes · Last reported as Chief Operating Officer in an SEC filing dated Mar 13, 2020
- Maggie Thompson · Last reported as SVP, Reimb. & Payer Relations in an SEC filing dated May 14, 2019
- Lynn Larson Blake · Last reported as Chief Financial Officer in an SEC filing dated Aug 20, 2018
- Stephen I Shapiro · Last reported as a director in an SEC filing dated Mar 6, 2017
TCMD Proposed Insider Sales (Form 144)
Latest: 2026-11-03What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-03 | King Laura G. | Director | 4,800 | $120.0K | 2026-11-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-20 | William W Burke | board of director | 15,000 | — | 2026-08-19 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-08-10 | Dodd Sheri Louise | Officer, Director | 10,978 | $323.2K | 2026-08-10 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-11 | Birkemeyer Elaine M. | Officer | 4,631 | $113.4K | 2026-05-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-25 | Burns Kristie | Officer | 4,000 | $113.9K | 2026-02-25 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-24 | Dodd Sheri Louise | Officer, Director | 10,993 | $318.1K | 2026-02-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-24 | Birkemeyer Elaine M. | Officer | 7,701 | $222.9K | 2026-02-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-24 | Burns Kristie | Officer | 6,246 | $180.8K | 2026-02-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-23 | Burns Kristie | Officer | 4,439 | $125.6K | 2026-02-23 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-23 | Dodd Sheri Louise | Officer, Director | 15,240 | $431.2K | 2026-02-23 | Fidelity Brokerage Services LLC | — | EDGAR |
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.02% | $15.8M | $74.3B | 2026-11-16 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $12.4M | — | 2026-10-31 |
| 3 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.03% | $8.5M | — | 2026-11-16 |
| 4 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.02% | $6.6M | — | 2026-11-16 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $5.8M | — | 2026-10-31 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.04% | $4.8M | $13.4B | 2026-11-16 |
| 7 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $4.4M | — | 2026-11-16 |
| 8 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.06% | $4.0M | $6.7B | 2026-11-16 |
| 9 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.15% | $3.6M | — | 2026-06-30 |
| 10 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $3.1M | — | 2026-10-31 |
| 11 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.4M | — | 2026-11-16 |
| 12 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.8M | — | 2026-11-16 |
| 13 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.16% | $1.8M | $1.2B | 2026-11-16 |
| 14 | NANC Unusual Whales Subversive Democratic Trading ETF | Nport | 0.64% | $1.8M | — | 2026-06-30 |
| 15 | VFMF Vanguard U.S. Multifactor ETF | Vanguard | 0.15% | $1.8M | — | 2026-11-16 |
| 16 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.43% | $1.6M | — | 2026-08-31 |
| 17 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.6M | — | 2026-10-31 |
| 18 | XHE State Street® SPDR® S&P® Health Care Equipment ETF | SPDR (State Street) | 1.01% | $1.6M | $154.2M | 2026-11-16 |
| 19 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.00% | $1.5M | $32.1B | 2026-11-16 |
| 20 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.04% | $1.4M | $3.2B | 2026-11-16 |
| 21 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.07% | $1.3M | — | 2026-11-16 |
| 22 | PSC Principal U.S. Small-Cap ETF | Nport | 0.05% | $1.2M | — | 2026-06-30 |
| 23 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.10% | $1.0M | $1.0B | 2026-11-16 |
| 24 | VAMO Cambria Value and Momentum ETF | Nport | 0.93% | $1.0M | — | 2026-07-31 |
| 25 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $968,781 | $13.5B | 2026-11-16 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $91.86M | $7.16M | $0.31 | $11.98M |
| Q2 '26 | 2026-06-30 | $85.70M | $7.79M | $0.34 | $3.25M |
| Q1 '26 | 2026-03-31 | $75.27M | $-1.76M | $-0.08 | $-339.00K |
| Q4 '25 | 2025-12-31 | $103.59M | $10.63M | $0.45 | $17.30M |
| Q3 '25 | 2025-09-30 | $85.75M | $8.21M | $0.36 | $10.34M |
| Q2 '25 | 2025-06-30 | $78.91M | $3.22M | $0.14 | $14.76M |
| Q1 '25 | 2025-03-31 | $61.27M | $-2.97M | $-0.13 | $417.00K |
| Q4 '24 | 2024-12-31 | $85.58M | $9.72M | $0.40 | $16.33M |
| Q3 '24 | 2024-09-30 | $73.09M | $5.16M | $0.21 | $10.26M |
| Q2 '24 | 2024-06-30 | $73.22M | $4.30M | $0.18 | $13.14M |
| Q1 '24 | 2024-03-31 | $61.09M | $-2.21M | $-0.09 | $924.00K |
| Q4 '23 | 2023-12-31 | $77.65M | $8.20M | $0.35 | $18.35M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
TCMD vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ISRG Intuitive Surgical Inc. | $145.9B | 49.1 | +20.5% | −27.8% | 28 |
| IDXX Idexx Laboratories Inc | $55.0B | 46.4 | +11.9% | +2.8% | 27 |
| GEHC GE HealthCare Technologies Inc. Common S | $37.8B | 17.3 | +6.9% | −1.1% | 19 |
| GKOS Glaukos Corporation | $13.8B | — | +46.9% | +114.2% | 26 |
| OSCR Oscar Health, Inc. | $8.6B | 12.3 | +54.9% | +73.6% | 16 |
| HAE Haemonetics Corporation | $5.6B | 53.9 | +4.1% | +51.0% | 16 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 16.2 | +1.9% | +40.3% | 31 |
| ENOV Enovis Corporation | $1.6B | — | +3.3% | −1.1% | 40 |
| TCMD Tactile Systems Technology, Inc. | $592M | 25.5 | +14.4% | −4.9% | 28 |
| Peer median | $11.2B | 31.9 | +9.4% | +21.6% | 27 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.